Csomor Philipp A, Stadler Renée R, Feldon Joram, Yee Benjamin K, Geyer Mark A, Vollenweider Franz X
University Hospital of Psychiatry Zurich, Experimental Psychopathology and Brain Imaging, Zurich, Switzerland.
Neuropsychopharmacology. 2008 Feb;33(3):497-512. doi: 10.1038/sj.npp.1301421. Epub 2007 Apr 25.
Schizophrenia patients exhibit deficits in sensory gating as indexed by reduced prepulse inhibition (PPI) and P50 suppression, which have been linked to psychotic symptom formation and cognitive deficits. Although recent evidence suggests that atypical antipsychotics might be superior over typical antipsychotics in reversing PPI and P50 suppression deficits not only in schizophrenia patients, but also in healthy volunteers exhibiting low levels of PPI, the impact of typical antipsychotics on these gating measures is less clear. To explore the impact of the dopamine D2-like receptor system on gating and cognition, the acute effects of haloperidol on PPI, P50 suppression, and cognition were assessed in 26 healthy male volunteers split into subgroups having low vs high PPI or P50 suppression levels using a placebo-controlled within-subject design. Haloperidol failed to increase PPI in subjects exhibiting low levels of PPI, but attenuated PPI in those subjects with high sensorimotor gating levels. Furthermore, haloperidol increased P50 suppression in subjects exhibiting low P50 gating and disrupted P50 suppression in individuals expressing high P50 gating levels. Independently of drug condition, high PPI levels were associated with superior strategy formation and execution times in a subset of cognitive tests. Moreover, haloperidol impaired spatial working memory performance and planning ability. These findings suggest that dopamine D2-like receptors are critically involved in the modulation of P50 suppression in healthy volunteers, and to a lesser extent also in PPI among subjects expressing high sensorimotor gating levels. Furthermore, the results suggest a relation between sensorimotor gating and working memory performance.
精神分裂症患者表现出感觉门控缺陷,这可通过预脉冲抑制(PPI)降低和P50抑制来衡量,这些缺陷与精神病性症状形成和认知缺陷有关。尽管最近的证据表明,非典型抗精神病药物不仅在精神分裂症患者中,而且在PPI水平较低的健康志愿者中,可能在逆转PPI和P50抑制缺陷方面优于典型抗精神病药物,但典型抗精神病药物对这些门控指标的影响尚不清楚。为了探究多巴胺D2样受体系统对门控和认知的影响,采用安慰剂对照的受试者内设计,对26名健康男性志愿者进行了分组,分为PPI或P50抑制水平低与高的亚组,评估了氟哌啶醇对PPI、P50抑制和认知的急性影响。氟哌啶醇未能增加PPI水平低的受试者的PPI,但减弱了感觉运动门控水平高的受试者的PPI。此外,氟哌啶醇增加了P50门控水平低的受试者的P50抑制,并破坏了P50门控水平高的个体的P50抑制。与药物状态无关,在一部分认知测试中,高PPI水平与更好的策略形成和执行时间相关。此外,氟哌啶醇损害了空间工作记忆表现和计划能力。这些发现表明,多巴胺D2样受体在健康志愿者中对P50抑制的调节中起关键作用,在感觉运动门控水平高的受试者中对PPI的调节作用较小。此外,结果表明感觉运动门控与工作记忆表现之间存在关联。